Adc Therapeutics SA

NYSE:ADCT

3.63

-0.19 (-4.97%)

7:39:13 PM EDT: $3.72 +0.09 (+2.48%)

Market Cap (Intraday)	349.31M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$18.93 Million
Adjusted EPS	-$0.44

See more estimates

10-Day MA	$3.68
50-Day MA	$3.43
200-Day MA	$2.98

See more pivots

Adc Therapeutics SA Stock, NYSE:ADCT

BiopÃ?Â?le, Route de la Corniche 3B, Epalinges, Vaud 1066

Switzerland

Phone: +41.212.653.02.00

Number of Employees: 162

http://www.adctherapeutics.com

Description

ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.